Global Human Chorionic Gonadotropin (hCG) Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

• In October 2023, Scripps Laboratories announced the development of a new era of recombinant proteins aimed at advancing research and diagnostic assay development. They tested recombinant proteins related to anemia, cardiology, and endocrinology. As native hormones could not fulfill the increasing demand, recombinant hormones such as TSH, hCG, FSH, LH, and prolactin were developed, tested, and approved for clinical diagnostics.

• In June 2022, Inception Fertility expanded its ecosystem by launching HavenCryo, a long-term solution for reproductive tissue storage and cryopreservation. This initiative aimed to offer a distinctive experience for fertility providers and patients alike.

The Global Human Chorionic Gonadotropin (hCG) Market can be segmented based on several factors, including product type, application, end-user, and region. One primary segmentation criterion is the type of hCG product, which encompasses pharmaceutical preparations and diagnostic assays. Pharmaceutical hCG products include injectable formulations used in assisted reproductive technologies (ART), such as ovulation induction and in vitro fertilization (IVF), as well as subcutaneous injections for the treatment of certain medical conditions, such as hypogonadism or delayed puberty. Diagnostic hCG assays, on the other hand, include urine and blood-based tests utilized for pregnancy testing and monitoring in clinical and home settings.

Another important segmentation factor in the Global Human Chorionic Gonadotropin Market is the application of hCG across different medical specialties and procedures. Within the field of reproductive medicine, hCG is primarily used to induce ovulation, support early pregnancy, and facilitate fertility treatments. In addition to ART, hCG is employed in ovulation induction protocols for women with ovulatory disorders or subfertility, optimizing the chances of conception. Moreover, hCG plays a vital role in pregnancy testing and monitoring, serving as a biomarker for early pregnancy detection and assessing the progression of pregnancy through serial hCG measurements.

End-user segmentation is also integral to understanding the Global Human Chorionic Gonadotropin Market, with key stakeholders including fertility clinics, hospitals, diagnostic laboratories, and home healthcare providers. Fertility clinics represent a significant end-user segment, specializing in the diagnosis and treatment of infertility and offering a wide range of reproductive services, including ART procedures involving hCG administration. Hospitals and diagnostic laboratories utilize hCG assays for pregnancy testing and monitoring, providing essential healthcare services to pregnant women and facilitating early intervention in cases of pregnancy complications. Home healthcare providers offer urine-based hCG pregnancy tests for convenient and accessible pregnancy testing in the comfort of patients' homes, contributing to the widespread availability and adoption of hCG-based diagnostic solutions.

Global Human Chorionic Gonadotropin (hCG) Segment Analysis

In this report, the Global Human Chorionic Gonadotropin (hCG) Market has been segmented by Technology, Therapeutic Area, End User and Geography.

Global Human Chorionic Gonadotropin (hCG) Market, Segmentation by Technology

The Global Human Chorionic Gonadotropin (hCG) Market has been segmented by Technology into Natural Source Extraction and Recombinant Technology.

The natural source extraction involves the isolation and purification of hCG from biological sources, such as urine collected from pregnant women. Historically, natural source hCG was the primary method of production for pharmaceutical-grade hCG preparations used in fertility treatments and medical therapies. This approach is associated with limitations, including variability in hCG purity and yield, as well as ethical considerations related to the collection of urine from pregnant donors.

In contrast, recombinant technology represents a more advanced and sustainable approach to hCG production within the Global Human Chorionic Gonadotropin Market. Recombinant hCG is synthesized using genetically engineered microorganisms, such as bacteria or yeast, that have been modified to produce human chorionic gonadotropin proteins. This method offers several advantages over natural source extraction, including greater consistency and purity of hCG products, reduced risk of contamination or impurities, and increased scalability and cost-effectiveness of production processes.

The adoption of recombinant technology in the Global Human Chorionic Gonadotropin Market reflects a broader trend towards biotechnological innovation and sustainable manufacturing practices in the pharmaceutical industry. By harnessing the power of genetic engineering, recombinant hCG manufacturers can produce high-quality hCG products with enhanced safety, efficacy, and reproducibility, meeting the growing demand for reliable fertility treatments and medical therapies worldwide. As recombinant technology continues to evolve, it is expected to play an increasingly prominent role in shaping the future of the Global Human Chorionic Gonadotropin Market, driving advancements in reproductive medicine and healthcare delivery.

Global Human Chorionic Gonadotropin (hCG) Market, Segmentation by Therapeutic Area

The Global Human Chorionic Gonadotropin (hCG) Market has been segmented by Therapeutic Area into Female Infertility Treatment, Oligospermic Treatment, Male Hypogonadism and Others.

The female infertility treatment, hCG plays a crucial role in triggering ovulation in women undergoing assisted reproductive technologies (ART) such as in vitro fertilization (IVF) or intrauterine insemination (IUI). By mimicking the action of luteinizing hormone (LH), hCG stimulates the release of mature eggs from the ovaries, facilitating the process of ovulation and improving the chances of conception in women with ovulatory disorders or unexplained infertility. The use of hCG in female infertility treatment is part of a comprehensive approach to fertility management, often combined with other hormonal medications and fertility procedures to optimize outcomes.

Oligospermic treatment represents another important therapeutic area for the Global Human Chorionic Gonadotropin (hCG) Market, particularly in cases of male infertility characterized by low sperm count or poor sperm motility. hCG therapy is utilized to stimulate the production of testosterone and enhance spermatogenesis in men with hypogonadism or primary testicular failure. By mimicking the action of luteinizing hormone (LH), hCG stimulates Leydig cells in the testes to produce testosterone, which in turn supports sperm production and maturation. This approach is commonly employed in conjunction with other treatments such as gonadotropin therapy or testosterone replacement therapy to address underlying hormonal imbalances and improve fertility outcomes in men with oligospermia.

Male hypogonadism represents another therapeutic area where hCG is utilized to restore hormonal balance and improve symptoms associated with testosterone deficiency. Hypogonadism refers to a condition characterized by inadequate production of testosterone by the testes, leading to symptoms such as decreased libido, erectile dysfunction, fatigue, and reduced muscle mass. hCG therapy is employed as a form of hormonal replacement therapy to stimulate testosterone production in men with hypogonadism, thereby alleviating symptoms and improving quality of life. By mimicking the action of LH, hCG stimulates Leydig cells to produce testosterone, restoring normal physiological levels of the hormone and addressing symptoms of hypogonadism.

Global Human Chorionic Gonadotropin (hCG) Market, Segmentation by End User

The Global Human Chorionic Gonadotropin (hCG) Market has been segmented by End User into Fertility Clinics, Research Institutes and Others.

The fertility clinics stand as a significant end-user segment within the market, specializing in the diagnosis and treatment of infertility. These clinics play a crucial role in providing assisted reproductive technologies (ART), such as in vitro fertilization (IVF) and ovulation induction, where hCG is commonly used to trigger ovulation and support early pregnancy. Fertility clinics utilize hCG preparations as part of tailored treatment protocols to optimize fertility outcomes for individuals and couples seeking to conceive.

Research institutes represent another important end-user segment in the Global Human Chorionic Gonadotropin Market, contributing to the advancement of scientific knowledge and innovation in reproductive medicine and endocrinology. Research institutions conduct studies and clinical trials to explore the physiological roles of hCG, investigate its therapeutic potential in various medical conditions, and develop novel hCG-based therapies and diagnostic assays. Research institutes play a critical role in elucidating the molecular mechanisms underlying hCG action, elucidating its interactions with reproductive hormones, and identifying potential targets for drug development.

The "Others" category in the segmentation of the Global Human Chorionic Gonadotropin Market encompasses a diverse array of end-users, including hospitals, diagnostic laboratories, pharmaceutical companies, and home healthcare providers. Hospitals and diagnostic laboratories utilize hCG assays for pregnancy testing and monitoring, providing essential healthcare services to pregnant women and facilitating early intervention in cases of pregnancy complications. Pharmaceutical companies may manufacture hCG preparations for medical use, including fertility treatments and hormone replacement therapy. Home healthcare providers offer urine-based hCG pregnancy tests for convenient and accessible pregnancy testing in the comfort of patients' homes, contributing to the widespread availability and adoption of hCG-based diagnostic solutions. The segmentation of the Global Human Chorionic Gonadotropin Market by end-user reflects the multifaceted nature of hCG utilization across various healthcare settings and research domains.

Global Human Chorionic Gonadotropin (hCG) Market, Segmentation by Geography

In this report, the Global Human Chorionic Gonadotropin (hCG) Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Global Human Chorionic Gonadotropin (hCG) Market Share (%), by Geographical Region, 2024

North America dominates the hCG market, driven by advanced healthcare infrastructure, high adoption rates of fertility treatments, and a significant prevalence of reproductive health disorders. The region is characterized by a well-established regulatory framework and strong emphasis on reproductive medicine, contributing to the demand for hCG products. North American healthcare facilities, including fertility clinics and gynecology centers, rely on hCG for various applications such as ovulation induction, assisted reproductive technologies (ART), and the treatment of hormone-related conditions.

Europe represents another significant market for human chorionic gonadotropin, with countries such as Germany, the UK, and France leading in terms of fertility treatments and reproductive healthcare services. The region's aging population, coupled with increasing infertility rates, drives the demand for hCG products for fertility enhancement and hormonal therapy. European healthcare facilities prioritize the use of hCG for ovulation induction in patients undergoing in vitro fertilization (IVF) and other ART procedures. The availability of hCG formulations in different dosage forms and delivery methods caters to the diverse needs of patients and healthcare providers in the region.

In the Asia Pacific, Middle East and Africa, and Latin America regions, the hCG market is influenced by factors such as rising healthcare spending, expanding access to fertility treatments, and growing awareness of reproductive health. In the Asia Pacific, countries like China, Japan, and India witness robust growth due to increasing infertility rates and rising demand for ART services. Healthcare facilities in these regions rely on hCG for ovulation induction and hormonal support in fertility treatments. In the Middle East and Africa, efforts to improve healthcare infrastructure and access drive demand for hCG products in reproductive medicine. In Latin America, market growth is fueled by healthcare reforms, investments in fertility clinics, and the adoption of international standards in reproductive healthcare. The global hCG market is shaped by regional healthcare dynamics and the demand for effective fertility treatments and hormone therapy across different geographies.

This report provides an in depth analysis of various factors that impact the dynamics of Global Human Chorionic Gonadotropin (hCG) Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Drivers

• Pregnancy Testing
• Assisted Reproduction

• Fertility Treatments : Fertility treatments represent a significant application of Human Chorionic Gonadotropin (hCG) within the Global hCG Market, particularly in the field of assisted reproductive technologies (ART). hCG is commonly utilized in fertility clinics as a key component of ovulation induction protocols, where it plays a crucial role in triggering the final maturation of oocytes (eggs) within the ovarian follicles. In women undergoing controlled ovarian stimulation for in vitro fertilization (IVF) or intrauterine insemination (IUI), hCG administration is carefully timed to induce ovulation, allowing for the retrieval of mature eggs for fertilization. This strategic use of hCG helps optimize the success rates of fertility treatments and improves the chances of conception for individuals and couples struggling with infertility.

  HCG is employed in the luteal phase support of ART cycles, where it serves to mimic the function of the corpus luteum by supporting the implantation and early development of embryos following embryo transfer. In IVF cycles, hCG may be administered in combination with other hormonal medications, such as progesterone supplements, to create an optimal uterine environment for embryo implantation and pregnancy establishment. By providing essential hormonal support during the critical early stages of pregnancy, hCG enhances the viability and success of ART procedures, ultimately increasing the likelihood of achieving a healthy pregnancy and live birth.

  Fertility treatments involving hCG extend beyond traditional IVF and IUI protocols to encompass a range of advanced reproductive techniques aimed at overcoming specific infertility challenges. For instance, hCG trigger protocols may be tailored to individuals with polycystic ovary syndrome (PCOS) or poor ovarian response, where alternative approaches to ovulation induction are required. Additionally, hCG may be utilized in combination with other fertility medications, such as gonadotropins or gonadotropin-releasing hormone (GnRH) agonists, to optimize ovarian stimulation and follicular development in patients undergoing fertility preservation, egg donation, or surrogacy arrangements. As fertility treatments continue to evolve and become increasingly personalized, hCG remains a fundamental component of ART protocols, contributing to the advancement of reproductive medicine and the realization of parenthood dreams for individuals and couples worldwide.

Restraints

• Regulatory Compliance
• Cost Constraints

• Safety Concerns : Safety concerns surrounding the Global Human Chorionic Gonadotropin (hCG) Market often revolve around its use in off-label or unregulated settings, particularly in the context of weight loss and athletic performance enhancement. While hCG is approved by regulatory agencies for specific medical purposes such as inducing ovulation and treating certain hormonal disorders, its use for non-approved indications raises safety issues. Off-label use of hCG for weight loss, for example, has been associated with potential risks such as electrolyte imbalances, gallstone formation, and cardiovascular complications. The lack of oversight and guidance regarding dosage, administration, and monitoring heightens safety concerns and underscores the importance of healthcare professionals' role in ensuring appropriate use of hCG.

  The proliferation of counterfeit or adulterated hCG products in the global market poses significant safety risks to consumers. Illicit manufacturers may produce hCG products that are substandard, contaminated, or misrepresented, compromising their efficacy and safety. Patients who unknowingly purchase counterfeit hCG formulations may be exposed to harmful substances or inadequate dosages, leading to adverse health outcomes. Regulatory authorities and healthcare organizations play a critical role in combating counterfeit drugs and safeguarding patient safety by enforcing stringent quality standards, conducting inspections, and issuing warnings against unauthorized hCG products.

  Another safety concern in the hCG market relates to the potential for misuse or abuse in athletic and bodybuilding communities seeking performance enhancement. Athletes and individuals may use hCG to manipulate hormone levels and circumvent doping regulations, posing risks to their health and integrity of sports. Misuse of hCG for performance enhancement can lead to hormonal imbalances, testicular atrophy, and other adverse effects. Efforts to combat doping and ensure fair competition in sports require collaboration among regulatory bodies, sports organizations, and healthcare professionals to educate athletes about the risks of hCG misuse and enforce anti-doping policies. Addressing safety concerns in the global hCG market requires regulatory vigilance, healthcare provider education, and public awareness to promote responsible use and protect patient health.

Opportunities

• Fertility Enhancement
• Diagnostic Innovation

• Reproductive Medicine : Reproductive medicine stands at the forefront of the Global Human Chorionic Gonadotropin (hCG) Market, with hCG playing a pivotal role in various assisted reproductive technologies (ART) and fertility treatments. One of the primary applications of hCG in reproductive medicine is ovulation induction. In women undergoing ovulation induction protocols for infertility treatment, hCG is administered to trigger the final maturation and release of eggs from ovarian follicles, facilitating timed intercourse or intrauterine insemination (IUI). This strategic use of hCG helps optimize the timing of ovulation and increases the chances of successful conception, particularly in cases of ovulatory disorders or subfertility.

  HCG is widely employed in in vitro fertilization (IVF) procedures, where it serves as a crucial component of ovarian stimulation protocols. In IVF cycles, hCG is administered to trigger the final maturation of multiple oocytes within the ovaries, ensuring synchronous follicle development and improving the yield of mature eggs for retrieval. Following egg retrieval, hCG may be used as a luteal phase support agent to promote endometrial receptivity and support early pregnancy until the placenta assumes hormone production. By optimizing ovarian response and supporting early embryo development, hCG contributes to the success of IVF treatments and enhances fertility outcomes for couples undergoing infertility treatment.

  HCG plays a vital role in pregnancy monitoring and support in the field of reproductive medicine. Following conception, hCG levels rise rapidly in early pregnancy, serving as a reliable biomarker for pregnancy detection and monitoring. Serial hCG measurements are performed to assess the progression of pregnancy, confirm fetal viability, and detect potential complications such as ectopic pregnancy or miscarriage. In cases of recurrent pregnancy loss or certain endocrine disorders, supplemental hCG may be administered to support early pregnancy and prevent miscarriage, highlighting the diverse applications of hCG in reproductive medicine and fertility care.

Key players in Global Human Chorionic Gonadotropin (hCG) Market include:

• Bristol Myers Squibb Company
• Merck & Co., Inc.
• Ferring B.V.
• Fresenius Kabi AG
• Cigna
• Sun Pharmaceutical Industries Ltd
• Lee BioSolutions Inc.
• Sanzyme
• Scripps Laboratories
• Lupin AB

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis